TY - JOUR
A2 - Ríos, José Luis
AU - Xi, Sisi
AU - Liske, Eckehard
AU - Wang, Shuyu
AU - Liu, Jianli
AU - Zhang, Zhonglan
AU - Geng, Li
AU - Hu, Lina
AU - Jiao, Chunfeng
AU - Zheng, Shurong
AU - Zepelin, Hans-Heinrich Henneicke-von
AU - Bai, Wenpei
PY - 2014
DA - 2014/03/02
TI - Effect of Isopropanolic Cimicifuga racemosa Extract on Uterine Fibroids in Comparison with Tibolone among Patients of a Recent Randomized, Double Blind, Parallel-Controlled Study in Chinese Women with Menopausal Symptoms
SP - 717686
VL - 2014
AB - Objective. Effect of isopropanolic Cimicifuga racemosa extract (iCR) on uterine fibroid size compared with tibolone. Method. The randomized, double-blind, controlled study in China enrolled 244 patients aged 40–60 years with menopausal symptoms (Kupperman Menopause Index ≥ 15). The participants were treated with either iCR of 40 mg crude drug/day (N=122) or tibolone 2.5 mg/day (N=122) orally for 3 months in 2004. Now, we investigated the subset of all women (N=62) with at least one uterine fibroid at onset of treatment for the effect of iCR (N = 34) on fibroid size compared with tibolone (N=28) by transvaginal ultrasonography. Results. The median myoma volume decreased upon iCR by as much as −30% (P=0.016) but increased upon tibolone by +4.7%. The percentage of volume change, mean diameter change and geometric mean diameter change of the iCR group compared to tibolone were statistically significant (P=0.016, 0.021, 0.016 respectively). Conclusion. Our results suggest that iCR (Remifemin) is a valid herbal medicinal product in patients with uterine myomas as it provides adequate relief from menopausal symptoms and inhibits growth of the myomas in contrast to tibolone.
SN - 1741-427X
UR - https://doi.org/10.1155/2014/717686
DO - 10.1155/2014/717686
JF - Evidence-Based Complementary and Alternative Medicine
PB - Hindawi Publishing Corporation
KW -
ER -